Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2023 shares | |
Cover [Abstract] | |
Document Type | 10-Q |
Amendment Flag | false |
Document Quarterly Report | true |
Document Period End Date | Jun. 30, 2023 |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | Q2 |
Document Transition Report | false |
Entity File Number | 0-15586 |
Entity Registrant Name | U.S. NeuroSurgical Holdings, Inc. |
Entity Central Index Key | 0001089815 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 47-5370333 |
Entity Address, Address Line One | 2400 Research Blvd, Suite 325 |
Entity Address, City or Town | Rockville |
Entity Address, State or Province | MD |
Entity Address, Postal Zip Code | 20850 |
City Area Code | 301 |
Local Phone Number | 208-8998 |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 7,892,185 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 776,000 | $ 1,537,000 |
Other current assets | 30,000 | 18,000 |
Total current assets | 806,000 | 1,555,000 |
Other assets: | ||
Due from related parties | 16,000 | 15,000 |
Investments in unconsolidated entities | 185,000 | 157,000 |
Total other assets | 201,000 | 172,000 |
Property and equipment: | ||
Operating lease right-of-use asset | 0 | 20,000 |
Total property and equipment | 0 | 20,000 |
TOTAL ASSETS | 1,007,000 | 1,747,000 |
Current liabilities: | ||
Operating lease right-of-use liability - current portion | 0 | 23,000 |
Accounts payable and accrued expenses | 7,000 | 86,000 |
Income taxes payable | 170,000 | 171,000 |
Total current liabilities | 177,000 | 280,000 |
Guarantee liability | 11,000 | 11,000 |
Total liabilities | 188,000 | 291,000 |
EQUITY | ||
Common stock - par value $.01; 25,000,000 shares authorized; 7,892,185 and 7,842,185 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively. | 79,000 | 78,000 |
Additional paid-in capital | 2,871,000 | 2,871,000 |
Accumulated deficit | (2,252,000) | (1,710,000) |
U.S. Neurosurgical Holdings, Inc. stockholders' equity | 698,000 | 1,239,000 |
Noncontrolling interests | 121,000 | 217,000 |
Total stockholders' equity | 819,000 | 1,456,000 |
TOTAL LIABILITIES AND EQUITY | $ 1,007,000 | $ 1,747,000 |
Related Party [Member] | ||
Other assets: | ||
Financing Receivable, after Allowance for Credit Loss, Noncurrent, Related Party, Type [Extensible Enumeration] | Due from related parties |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Jun. 30, 2023 | Dec. 31, 2022 |
EQUITY | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
Common stock, shares issued (in shares) | 7,892,185 | 7,842,185 |
Common stock, shares outstanding (in shares) | 7,892,185 | 7,842,185 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] | ||||
Revenue | $ 0 | $ 0 | $ 0 | $ 0 |
Costs and expenses: | ||||
Selling, general and administrative | 242,000 | 292,000 | 371,000 | 652,000 |
Total | 242,000 | 292,000 | 371,000 | 652,000 |
Operating loss | (242,000) | (292,000) | (371,000) | (652,000) |
Total other expense | ||||
Loss from investments in unconsolidated entities, net | (269,000) | (998,000) | (267,000) | (1,131,000) |
Total other expense | (269,000) | (998,000) | (267,000) | (1,131,000) |
(Loss) income before income taxes | (511,000) | (1,290,000) | (638,000) | (1,783,000) |
Provision for income taxes | 0 | 1,000 | 0 | 3,000 |
Net (loss) income | (511,000) | (1,291,000) | (638,000) | (1,786,000) |
Net loss attributable to noncontrolling interests | 77,000 | 194,000 | 96,000 | 268,000 |
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc. | $ (434,000) | $ (1,097,000) | $ (542,000) | $ (1,518,000) |
Basic net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc (in dollars per share) | $ (0.05) | $ (0.14) | $ (0.07) | $ (0.19) |
Diluted net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc (in dollars per share) | $ (0.05) | $ (0.14) | $ (0.07) | $ (0.19) |
Weighted average common shares outstanding, basic (in shares) | 7,892,185 | 7,792,185 | 7,892,185 | 7,792,185 |
Weighted average common shares outstanding, diluted (in shares) | 7,892,185 | 7,792,185 | 7,892,185 | 7,792,185 |
CONSOLIDATED STATEMENTS OF EQUI
CONSOLIDATED STATEMENTS OF EQUITY - USD ($) | Common Stock [Member] | Additional Paid-In Capital [Member] | (Accumulated Deficit) Retained Earnings [Member] | U.S. Neurosurgical Holdings, Inc. Equity [Member] | Noncontrolling Interests [Member] | Total |
Balance at Dec. 31, 2021 | $ 78,000 | $ 2,871,000 | $ (373,000) | $ 2,576,000 | $ 452,000 | $ 3,028,000 |
Balance (in shares) at Dec. 31, 2021 | 7,792,185 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of common stock as compensation | $ 0 | 0 | 0 | 0 | ||
Issuance of common stock as compensation (in shares) | 50,000 | |||||
Net loss | $ 0 | 0 | (1,337,000) | (1,337,000) | (235,000) | (1,572,000) |
Balance at Dec. 31, 2022 | $ 78,000 | 2,871,000 | (1,710,000) | 1,239,000 | 217,000 | $ 1,456,000 |
Balance (in shares) at Dec. 31, 2022 | 7,842,185 | 7,842,185 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of common stock as compensation | $ 1,000 | 1,000 | 0 | $ 1,000 | ||
Issuance of common stock as compensation (in shares) | 50,000 | |||||
Net loss | $ 0 | 0 | (542,000) | (542,000) | (96,000) | (638,000) |
Balance at Jun. 30, 2023 | $ 79,000 | $ 2,871,000 | $ (2,252,000) | $ 698,000 | $ 121,000 | $ 819,000 |
Balance (in shares) at Jun. 30, 2023 | 7,892,185 | 7,892,185 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Cash flows from operating activities: | |||||
Net loss | $ (511,000) | $ (1,291,000) | $ (638,000) | $ (1,786,000) | $ (1,572,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Amortization of operating lease right-of-use asset | 20,000 | 19,000 | |||
Loss from investments in unconsolidated entities, net | 266,000 | 1,131,000 | |||
Distributed earnings from unconsolidated entities | 23,000 | 11,000 | |||
Deferred income taxes | 0 | 0 | |||
Changes in: | |||||
Income taxes payable | (1,000) | (183,000) | |||
Other current assets | (12,000) | 8,000 | |||
Accounts payable and accrued expenses | (79,000) | (86,000) | |||
Operating lease right-of-use liability | (22,000) | (21,000) | |||
Net cash used in operating activities | (443,000) | (907,000) | |||
Cash flows from investing activities: | |||||
Advances to unconsolidated entities | (305,000) | (175,000) | |||
Repayments from loans to unconsolidated entities | 44,000 | 0 | |||
Capital contributions to unconsolidated entities | (57,000) | 0 | |||
Net cash used in investing activities | (318,000) | (175,000) | |||
Cash flows from financing activities: | |||||
Repayment of finance lease obligations | 0 | 0 | |||
Net cash used in financing activities | 0 | 0 | |||
Net change in cash and cash equivalents | (761,000) | (1,082,000) | |||
Cash and cash equivalents - beginning of period | 1,537,000 | 2,178,000 | 2,178,000 | ||
Cash and cash equivalents - end of period | $ 776,000 | $ 1,096,000 | 776,000 | 1,096,000 | $ 1,537,000 |
Cash paid for: | |||||
Interest | 1,000 | 0 | |||
Income taxes | $ 0 | $ 183,000 |
Basis of Preparation
Basis of Preparation | 6 Months Ended |
Jun. 30, 2023 | |
Basis of Preparation [Abstract] | |
Basis of Preparation | Note A - Basis of Preparation The accompanying Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and Subsidiaries (the “Company”) as of June 30, 2023, and 2022, are unaudited. However, in the opinion of management, such statements include all adjustments necessary for a fair statement of the information presented therein. The Consolidated Balance Sheet at December 31, 2022, has been derived from the audited Consolidated Financial Statements at that date appearing in the Company’s Annual Report on Form 10-K. All amounts are shown in nearest thousands in the Consolidated Financial Statements and accompanying notes therein . Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements. Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years. The only change to the Company’s equity in the six months ended June 30, 2023, and 2022 was net loss for the periods. The Company issued 50,000 shares of stock to a new Board Member in April 2023. The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification (“ASC”) Topic 842, Leases The tables below present financial information associated with our leases. Classification June 30, 2023 June 30, 2022 Assets Long-term Operating lease assets Operating lease right-of-use asset $ - $ 40,000 Total leased assets $ - $ 4,000 Liabilities Current Operating lease liabilities Operating lease right-of-use liability - current portion $ - $ 45,000 Long-term Operating lease liabilities Operating lease right-of-use liability - net of current portion $ - $ - Total lease liabilities $ - $ 45,000 Lease Cost Operating lease cost Selling, general and administrative $ 10,000 $ 21,000 Finance lease cost Interest on lease liabilities Interest expense - - Sublease income Interest income - sales-type sublease - - Net lease expense $ 10,000 $ 21,000 Maturity of lease liabilities (as of June 30 2023 Operating lease 2023 - Total $ - Less amount representing interest - Present value of lease liabilities $ - Discount rate 5.850 % |
The Southern California Regiona
The Southern California Regional Gamma Knife Center | 6 Months Ended |
Jun. 30, 2023 | |
The Southern California Regional Gamma Knife Center [Abstract] | |
The Southern California Regional Gamma Knife Center | Note B – The Southern California Regional Gamma Knife Center During 2007, the Company, through a noncontrolling interest in joint ventures, managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California. Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife. CGK leases the gamma knife from NeuroPartners LLC, which holds the gamma knife equipment. In addition to returns on its ownership interests, USNC expects to receive fees for management services relating to the facility. USNC is a 20% owner of NeuroPartners LLC and owns 39% of CGK. Construction of the SARH gamma knife center was completed in December 2008 and the first patient was treated in January 2009. The project has been funded principally by outside investors. While the Company, through its joint ventures, has led the effort in organizing the business and overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal. At June 30, 2023, and December 31, 2022, the Company had no recorded investment of NeuroPartners LLC and CGK. For the six months ended June 30, 2023, and 2022, the Company’s equity in loss of NeuroPartners LLC and CGK was $63,000 and $5,000, respectively, but was not recorded due to prior losses, resulting in no recorded investment at June 30, 2023, and December 31, 2022. At June 30, 2023, and December 31, 2022, amounts due from related parties was $0 and $47,000, respectively. The SARH gamma knife center treated its last patients during the second quarter of 2023, and the Company is currently in negotiations with the hospital center and a removal company for the removal of the equipment from the SARH center. It is estimated it will cost approximately $600,000. The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK: NeuroPartners LLC and CGK Condensed Combined Income Statement Information Six Months Ended June 30, 2023 2022 Patient revenue $ 136,000 $ 170,000 Net loss $ (75,000 ) $ 8,000 USNC’s equity in (loss) earnings of NeuroPartners LLC and CGK $ (63,000 ) $ (5,000 ) Three Months Ended June 30, 2023 2022 Patient Revenue $ 40,000 $ 277,000 Net loss $ (38,000 ) $ (27,000 ) USNC’s equity in earnings of NeuroPartners, LLC and CGK $ (37,000 ) $ (28,000 ) NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information June 30, December 31, 2023 2022 Current assets $ 363,000 $ 375,000 Noncurrent assets - 42,000 Total assets $ 363,000 $ 417,000 Current liabilities $ 653,000 $ 632,000 Noncurrent liabilities - - Equity (290,000 ) (215,000 ) Total liabilities and equity $ 363,000 $ 417,000 |
Boca Oncology Partners
Boca Oncology Partners | 6 Months Ended |
Jun. 30, 2023 | |
Boca Oncology Partners [Abstract] | |
Boca Oncology Partners | Note C – Boca Oncology Partners During the quarter ended June 30, 2011, the Company, through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida. In June 2011, BOPRE, an affiliated entity, purchased a 20% interest in Boca West IMP, owner of a medical office building in West Boca, Florida in which BOP operates. BOP occupies 6,000 square feet of the 32,000 square foot building. The Company invested $225,000 initially and had a 22.5% interest in BOP and BOPRE. In February 2014, the Company and other members sold their interests in BOP. In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP. During the years ended December 31, 2018, and 2017, several investors relinquished part of their ownership interest in BOPRE, and those interests were distributed among the remaining investors in relationship to their percentages owned. During 2021 and 2022, additional members relinquished their ownership to USNC. As a result, the Company now holds a 23.10% ownership interest in BOPRE, which it accounts for under the equity method. The Company’s recorded investment in BOPRE is $185,000 and $157,000 at June 30, 2023, and December 31, 2022, respectively The following tables present the summarized financial information of BOPRE: BOPRE Condensed Income Statement Information Six Months Ended June 30, 2023 2022 Rental Income $ - $ - Net income $ 18,000 $ 31,000 USNC’s equity in earnings of BOPRE $ 4,000 $ 8,000 Three Months Ended June 30, 2023 2022 Rental Income $ - $ - Net income $ 7,000 $ 14,000 USNC’s equity in earnings of BOPRE $ 2,000 $ 4,000 BOPRE Condensed Balance Sheet Information June 30, December 31, 2023 2022 Current assets $ 41,000 $ 123,000 Noncurrent assets 757,000 757,000 Total assets $ 798,000 $ 880,000 Current liabilities $ - $ - Noncurrent liabilities - - Equity 798,000 880,000 Total liabilities and equity $ 798,000 $ 880,000 |
Medical Oncology Partners
Medical Oncology Partners | 6 Months Ended |
Jun. 30, 2023 | |
Medical Oncology Partners [Abstract] | |
Medical Oncology Partners | Note D - Medical Oncology Partners In April 2015, MOP, was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in UOMA. USNC was not a member of MOP at the time of formation as it was not able to participate due to the fact that USNC was not a physician. Nevertheless, USNC wished to eventually obtain an equity interest in MOP and loaned Dr. Jaime Lozano, the principal investor in MOP and a co-investor in FOP, $173,000. Dr. Lozano used these funds, along with an equal amount of his own funds (a total of $345,000), to purchase a 76.67% interest in MOP. Other investors paid a further $105,000 for the remaining equity in MOP. MOP used the $450,000 of financing to acquire a 100% equity interest in UOMA. An application was filed for a waiver to allow USNC to hold an equity interest notwithstanding the physician requirement and on December 22, 2016, USNC was cleared to become a part owner of MOP. Dr. Lozano agreed to exchange half of his membership interest to USNC in settlement of the note to USNC. USNC and Dr. Lozano also agreed to share equally in providing a 5% equity interest in MOP to an additional investor as a consulting fee for services rendered in the administration of MOP and UOMA. At December 22, 2016, USNC owned 35.83% of MOP with an initial carrying value of $161,000. The Company recorded its share of losses of $12,000 for the period from December 22, 2016 to December 31, 2016, against its investment which resulted in a reduction of its equity investment to $149,000. On December 31, 2022, MOP/UOMA sold their assets to One Care Oncology Partners, LLC for $2,060,000. USN Corona netted approximately $1.3 million from the proceeds for management fees to date. Some funds were held in escrow until post-closing adjustments were made, which has not been finalized as of June 30, 2023. |
CB Oncology Partners
CB Oncology Partners | 6 Months Ended |
Jun. 30, 2023 | |
CB Oncology Partners [Abstract] | |
CB Oncology Partners | Note E - CB Oncology Partners CBOP was organized September 1, 2017, to acquire the rights of the new center from FOP. USNC originally had a 24% equity interest in CBOP. Beginning in October of 2017, CBOP began paying the remainder of the costs associated with opening the center. CBOP had no assets at the end of 2017. The medical center opened and treated its first patient in January of 2018. Effective November 15, 2019, FOP transferred to, and CBOP assumed, a loan with BB&T bank, that it had entered in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and extended the loan to July of 2027. In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions were not met and, accordingly, the Company’s equity interest in CBOP increased to 28.58% in June 2020. In May 2023, CBOP made an additional $200,000 capital call to its members. The Company met its call of $57,000 and other members contributed $76,000. As was the case with the previous capital call, the remaining contributions are not expected to be met and accordingly, the Company’s equity interest in CBOP increased to 30.23% in May 2023. Amounts due from CBOP at June 30, 2023, total $565,000 of outstanding principal, less $550,000 of allowances, for a net receivable of $15,000 as compared to $163,000 of outstanding principal, less $156,000 of allowances, for a net receivable of $6,000 at December 31,2022. The Company records increases in the allowance, when applicable, as a component of loss from investments in unconsolidated. For the six months ended June 30, 2023 and 2022, the Company’s equity in loss of CBOP was $173,000 and $68,000, respectively, but was not recorded due to prior losses. Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company. However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic performance, the entity is not consolidated, but certain disclosures are provided herein. The following table presents the summarized financial information of CBOP: CBOP Condensed Income Statement Information Six Months Ended June 30, 2023 2022 Patient revenue $ 761,000 $ 1,026,000 Net (loss) income $ (607,000 ) $ (237,000 ) USNC’s equity in (loss) income of CBOP $ (173,000 ) $ (68,000 ) Three Months Ended June 30, 2023 2022 Patient revenue $ 443,000 $ 44,000 Net (loss) income $ (320,000 ) $ (191,000 ) USNC’s equity in (loss) income of CBOP $ (91,000 ) $ (55,000 ) CBOP Condensed Balance Sheet Information June 30, December 31, 2023 2022 Current assets $ 347,000 $ 405,000 Noncurrent assets 2,763,000 3,056,000 Total assets $ 3,110,000 $ 3,461,000 Current liabilities $ 3,909,000 $ 975,000 Noncurrent liabilities 2,868,000 5,680,000 Deficit (3,667,000 ) (3,194,000 ) Total liabilities and deficit $ 3,110,000 $ 3,461,000 |
Elite Health
Elite Health | 6 Months Ended |
Jun. 30, 2023 | |
Elite Health [Abstract] | |
Elite Health | Note F – Elite Health Effective October 1, 2021, U.S. NeuroSurgical, Inc. (“USN”), acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation (“Elite Health”). The transaction with Elite Health was structured as an investment by Elite Health shareholders in USN, and as such did not have an immediate effect on the percentage ownership of the shareholders of the Company. However, the Company’s interest in USN, which currently holds substantially all of the interest in the Company’s businesses and operations, was effectively diluted by 15% as a result of the issuance of the new USN shares to the former of Elite Health. Elite Health is a private company with a limited operating history. It was formed in 2017 with the purpose of establishing a managed care organization that will operate as a Medicare Advantage plan for seniors. It is expected that Elite Health will operate in California, initially San , Riverside, and Orange Counties, with the objective of addressing the growing number of Medicare eligible seniors in those markets. Elite Health is in the process of applying for a Knox Keene license to operate a Medicare Advantage plan in California and has taken preliminary steps toward identifying a network of providers who are well-versed in the healthcare needs of seniors in the communities in which they practice. If Elite Health is successful in obtaining the license, establishing Elite Health as an operating entity will require significant investment not currently available to the Company. The Company is currently exploring opportunities to provide the necessary funding to proceed with activities required to launch Elite Health. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2023 | |
Income Taxes [Abstract] | |
Income Taxes | Note G – Income Taxes The Company’s income tax rate, which includes federal and state income taxes, was 0% for the six months ended June 30, 2023, and 2022. |
Basis of Preparation (Tables)
Basis of Preparation (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Basis of Preparation [Abstract] | |
Financial Information Associated with our Leases | The tables below present financial information associated with our leases. Classification June 30, 2023 June 30, 2022 Assets Long-term Operating lease assets Operating lease right-of-use asset $ - $ 40,000 Total leased assets $ - $ 4,000 Liabilities Current Operating lease liabilities Operating lease right-of-use liability - current portion $ - $ 45,000 Long-term Operating lease liabilities Operating lease right-of-use liability - net of current portion $ - $ - Total lease liabilities $ - $ 45,000 Lease Cost Operating lease cost Selling, general and administrative $ 10,000 $ 21,000 Finance lease cost Interest on lease liabilities Interest expense - - Sublease income Interest income - sales-type sublease - - Net lease expense $ 10,000 $ 21,000 |
Maturity of Lease Liabilities | Maturity of lease liabilities (as of June 30 2023 Operating lease 2023 - Total $ - Less amount representing interest - Present value of lease liabilities $ - Discount rate 5.850 % |
The Southern California Regio_2
The Southern California Regional Gamma Knife Center (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Neuro Partners LLC and CGK [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK: NeuroPartners LLC and CGK Condensed Combined Income Statement Information Six Months Ended June 30, 2023 2022 Patient revenue $ 136,000 $ 170,000 Net loss $ (75,000 ) $ 8,000 USNC’s equity in (loss) earnings of NeuroPartners LLC and CGK $ (63,000 ) $ (5,000 ) Three Months Ended June 30, 2023 2022 Patient Revenue $ 40,000 $ 277,000 Net loss $ (38,000 ) $ (27,000 ) USNC’s equity in earnings of NeuroPartners, LLC and CGK $ (37,000 ) $ (28,000 ) NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information June 30, December 31, 2023 2022 Current assets $ 363,000 $ 375,000 Noncurrent assets - 42,000 Total assets $ 363,000 $ 417,000 Current liabilities $ 653,000 $ 632,000 Noncurrent liabilities - - Equity (290,000 ) (215,000 ) Total liabilities and equity $ 363,000 $ 417,000 |
Boca Oncology Partners (Tables)
Boca Oncology Partners (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following tables present the summarized financial information of BOPRE: BOPRE Condensed Income Statement Information Six Months Ended June 30, 2023 2022 Rental Income $ - $ - Net income $ 18,000 $ 31,000 USNC’s equity in earnings of BOPRE $ 4,000 $ 8,000 Three Months Ended June 30, 2023 2022 Rental Income $ - $ - Net income $ 7,000 $ 14,000 USNC’s equity in earnings of BOPRE $ 2,000 $ 4,000 BOPRE Condensed Balance Sheet Information June 30, December 31, 2023 2022 Current assets $ 41,000 $ 123,000 Noncurrent assets 757,000 757,000 Total assets $ 798,000 $ 880,000 Current liabilities $ - $ - Noncurrent liabilities - - Equity 798,000 880,000 Total liabilities and equity $ 798,000 $ 880,000 |
CB Oncology Partners (Tables)
CB Oncology Partners (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
CB Oncology Partners LLC [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Equity Method Investment Summarized Financial Information | The following table presents the summarized financial information of CBOP: CBOP Condensed Income Statement Information Six Months Ended June 30, 2023 2022 Patient revenue $ 761,000 $ 1,026,000 Net (loss) income $ (607,000 ) $ (237,000 ) USNC’s equity in (loss) income of CBOP $ (173,000 ) $ (68,000 ) Three Months Ended June 30, 2023 2022 Patient revenue $ 443,000 $ 44,000 Net (loss) income $ (320,000 ) $ (191,000 ) USNC’s equity in (loss) income of CBOP $ (91,000 ) $ (55,000 ) CBOP Condensed Balance Sheet Information June 30, December 31, 2023 2022 Current assets $ 347,000 $ 405,000 Noncurrent assets 2,763,000 3,056,000 Total assets $ 3,110,000 $ 3,461,000 Current liabilities $ 3,909,000 $ 975,000 Noncurrent liabilities 2,868,000 5,680,000 Deficit (3,667,000 ) (3,194,000 ) Total liabilities and deficit $ 3,110,000 $ 3,461,000 |
Basis of Preparation (Details)
Basis of Preparation (Details) - USD ($) | 1 Months Ended | 6 Months Ended | 12 Months Ended | |
Apr. 30, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Long-term Assets [Abstract] | ||||
Operating lease right-of-use asset | $ 0 | $ 40,000 | $ 20,000 | |
Total leased assets | 0 | 4,000 | ||
Current Liabilities [Abstract] | ||||
Operating lease right-of-use liability - current portion | 0 | 45,000 | $ 23,000 | |
Long-term Liabilities [Abstract] | ||||
Operating lease right-of-use liability - net of current portion | 0 | 0 | ||
Total lease liabilities | 0 | 45,000 | ||
Lease Cost [Abstract] | ||||
Net lease expense | 10,000 | 21,000 | ||
Operating lease [Abstract] | ||||
2023 | 0 | |||
Total | 0 | |||
Less amount representing interest | 0 | |||
Present value of lease liabilities | $ 0 | |||
Discount rate | 5.85% | |||
Selling, General and Administrative Expenses [Member] | ||||
Lease Cost [Abstract] | ||||
Operating lease cost | $ 10,000 | 21,000 | ||
Interest Expense [Member] | ||||
Lease Cost [Abstract] | ||||
Finance lease cost, interest on lease liabilities | 0 | 0 | ||
Interest Income - Sales-type Sublease [Member] | ||||
Lease Cost [Abstract] | ||||
Sublease income | $ 0 | $ 0 | ||
Common Stock [Member] | ||||
Stockholders' Equity [Abstract] | ||||
Issuance of common stock (in shares) | 50,000 | 50,000 | ||
Common Stock [Member] | New Board Member [Member] | ||||
Stockholders' Equity [Abstract] | ||||
Issuance of common stock (in shares) | 50,000 |
The Southern California Regio_3
The Southern California Regional Gamma Knife Center (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
The Southern California Regional Gamma Knife Center [Abstract] | ||||||
Renovation installation and operation agreement period | 14 years | |||||
Due from related parties | $ 16,000 | $ 16,000 | $ 15,000 | |||
Condensed Income Statement Information [Abstract] | ||||||
Patient revenue | 0 | $ 0 | 0 | $ 0 | ||
Net loss | (511,000) | (1,291,000) | (638,000) | (1,786,000) | (1,572,000) | |
USNC's equity in (loss) earnings | (269,000) | (998,000) | (267,000) | (1,131,000) | ||
Condensed Balance Sheet Information [Abstract] | ||||||
Current assets | 806,000 | 806,000 | 1,555,000 | |||
TOTAL ASSETS | 1,007,000 | 1,007,000 | 1,747,000 | |||
Current liabilities | 177,000 | 177,000 | 280,000 | |||
Equity | 819,000 | 819,000 | 1,456,000 | $ 3,028,000 | ||
TOTAL LIABILITIES AND EQUITY | 1,007,000 | 1,007,000 | 1,747,000 | |||
Neuro Partners LLC and CGK [Member] | ||||||
The Southern California Regional Gamma Knife Center [Abstract] | ||||||
Recorded amount of equity method income (loss) | 0 | 0 | ||||
Condensed Income Statement Information [Abstract] | ||||||
Patient revenue | 40,000 | 277,000 | 136,000 | 170,000 | ||
Net loss | (38,000) | (27,000) | (75,000) | 8,000 | ||
Condensed Balance Sheet Information [Abstract] | ||||||
Current assets | 363,000 | 363,000 | 375,000 | |||
Noncurrent assets | 0 | 0 | 42,000 | |||
TOTAL ASSETS | 363,000 | 363,000 | 417,000 | |||
Current liabilities | 653,000 | 653,000 | 632,000 | |||
Noncurrent liabilities | 0 | 0 | 0 | |||
Equity | (290,000) | (290,000) | (215,000) | |||
TOTAL LIABILITIES AND EQUITY | 363,000 | 363,000 | 417,000 | |||
SARH center [Member] | ||||||
The Southern California Regional Gamma Knife Center [Abstract] | ||||||
Expected equipment cost | $ 600,000 | $ 600,000 | ||||
Neuro Partners LLC [Member] | ||||||
The Southern California Regional Gamma Knife Center [Abstract] | ||||||
Ownership percentage | 20% | 20% | ||||
CGK [Member] | ||||||
The Southern California Regional Gamma Knife Center [Abstract] | ||||||
Ownership percentage | 39% | 39% | ||||
CGK [Member] | Related Party [Member] | ||||||
The Southern California Regional Gamma Knife Center [Abstract] | ||||||
Due from related parties | $ 0 | $ 0 | $ 47,000 | |||
Neuro Partners LLC and CGK [Member] | ||||||
Condensed Income Statement Information [Abstract] | ||||||
USNC's equity in (loss) earnings | $ (37,000) | $ (28,000) | $ (63,000) | $ (5,000) |
Boca Oncology Partners (Details
Boca Oncology Partners (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2012 | Jun. 30, 2011 USD ($) | Jun. 30, 2023 USD ($) ft² | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) ft² | Jun. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Boca Oncology Partners [Abstract] | ||||||||
Recorded investments | $ 185,000 | $ 185,000 | $ 157,000 | |||||
Condensed Income Statement Information [Abstract] | ||||||||
Net income | (511,000) | $ (1,291,000) | (638,000) | $ (1,786,000) | (1,572,000) | |||
USNC's equity in (loss) income | (269,000) | (998,000) | (267,000) | (1,131,000) | ||||
Condensed Balance Sheet Information [Abstract] | ||||||||
Current assets | 806,000 | 806,000 | 1,555,000 | |||||
TOTAL ASSETS | 1,007,000 | 1,007,000 | 1,747,000 | |||||
Current liabilities | 177,000 | 177,000 | 280,000 | |||||
Equity | 819,000 | 819,000 | 1,456,000 | $ 3,028,000 | ||||
TOTAL LIABILITIES AND EQUITY | 1,007,000 | 1,007,000 | 1,747,000 | |||||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | ||||||||
Condensed Income Statement Information [Abstract] | ||||||||
Rental income | 0 | 0 | 0 | 0 | ||||
Net income | 7,000 | 14,000 | 18,000 | 31,000 | ||||
Condensed Balance Sheet Information [Abstract] | ||||||||
Current assets | 41,000 | 41,000 | 123,000 | |||||
Noncurrent assets | 757,000 | 757,000 | 757,000 | |||||
TOTAL ASSETS | 798,000 | 798,000 | 880,000 | |||||
Current liabilities | 0 | 0 | 0 | |||||
Noncurrent liabilities | 0 | 0 | 0 | |||||
Equity | 798,000 | 798,000 | 880,000 | |||||
TOTAL LIABILITIES AND EQUITY | $ 798,000 | $ 798,000 | 880,000 | |||||
Boca Oncology Partners, LLC [Member] | ||||||||
Boca Oncology Partners [Abstract] | ||||||||
Area of real estate property (in square foot) | ft² | 6,000 | 6,000 | ||||||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | ||||||||
Boca Oncology Partners [Abstract] | ||||||||
Ownership percentage | 23.10% | 23.10% | ||||||
Recorded investments | $ 185,000 | $ 185,000 | $ 157,000 | |||||
Condensed Income Statement Information [Abstract] | ||||||||
USNC's equity in (loss) income | $ 2,000 | $ 4,000 | $ 4,000 | $ 8,000 | ||||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | Boca West IMP [Member] | ||||||||
Boca Oncology Partners [Abstract] | ||||||||
Percentage of interest in medical office building | 20% | |||||||
Ownership percentage | 23.75% | |||||||
Additional investor purchased ownership percentage | 3.75% | |||||||
BOP and BOPRE [Member] | ||||||||
Boca Oncology Partners [Abstract] | ||||||||
Area of real estate property (in square foot) | ft² | 32,000 | 32,000 | ||||||
Investments in unconsolidated entities | $ 225,000 | |||||||
Ownership percentage | 22.50% |
Medical Oncology Partners (Deta
Medical Oncology Partners (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||||
Dec. 31, 2022 | Dec. 31, 2016 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 23, 2016 | |
Medical Oncology Partners [Abstract] | |||||||
Carrying value of investment | $ 157,000 | $ 185,000 | $ 185,000 | ||||
USNC's equity in (loss) income | (269,000) | $ (998,000) | $ (267,000) | $ (1,131,000) | |||
USNC [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Proceeds from sale of assets | 2,060,000 | ||||||
Payment for management fees | $ 1,300,000 | ||||||
MOP [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Equity interest percentage to be acquired by subsidiary | 100% | ||||||
Investments in unconsolidated entities | $ 450,000 | ||||||
USNC's equity in (loss) income | $ (12,000) | ||||||
MOP [Member] | Other Investor [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Investments in unconsolidated entities | 105,000 | ||||||
MOP [Member] | USNC [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Investments in unconsolidated entities | 173,000 | ||||||
Ownership percentage | 35.83% | ||||||
Carrying value of investment | $ 149,000 | 149,000 | $ 161,000 | ||||
MOP [Member] | USNC [Member] | Dr. Jaime Lozano [Member] | |||||||
Medical Oncology Partners [Abstract] | |||||||
Investments in unconsolidated entities | $ 345,000 | ||||||
Ownership percentage | 76.67% | 76.67% | |||||
Percentage of equity interest to an additional investor as a consulting fee for services | 5% |
CB Oncology Partners (Details)
CB Oncology Partners (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
May 31, 2023 | Jun. 30, 2020 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Sep. 02, 2017 | |
CB Oncology Partners [Abstract] | |||||||||
Due from related parties | $ 16,000 | $ 16,000 | $ 15,000 | ||||||
USNC's equity in (loss) income | (269,000) | $ (998,000) | (267,000) | $ (1,131,000) | |||||
Condensed Income Statement Information [Abstract] | |||||||||
Patient revenue | 0 | 0 | 0 | 0 | |||||
Net (loss) income | (511,000) | (1,291,000) | (638,000) | (1,786,000) | (1,572,000) | ||||
USNC's equity in (loss) income | (269,000) | (998,000) | (267,000) | (1,131,000) | |||||
Condensed Balance Sheet Information [Abstract] | |||||||||
Current assets | 806,000 | 806,000 | 1,555,000 | ||||||
TOTAL ASSETS | 1,007,000 | 1,007,000 | 1,747,000 | ||||||
Current liabilities | 177,000 | 177,000 | 280,000 | ||||||
Deficit | 819,000 | 819,000 | 1,456,000 | $ 3,028,000 | |||||
TOTAL LIABILITIES AND EQUITY | 1,007,000 | 1,007,000 | 1,747,000 | ||||||
CB Oncology Partners LLC [Member] | |||||||||
CB Oncology Partners [Abstract] | |||||||||
Allowances on outstanding amount | 550,000 | 550,000 | 156,000 | ||||||
Condensed Income Statement Information [Abstract] | |||||||||
Patient revenue | 443,000 | 44,000 | 761,000 | 1,026,000 | |||||
Net (loss) income | (320,000) | (191,000) | (607,000) | (237,000) | |||||
Condensed Balance Sheet Information [Abstract] | |||||||||
Current assets | 347,000 | 347,000 | 405,000 | ||||||
Noncurrent assets | 2,763,000 | 2,763,000 | 3,056,000 | ||||||
TOTAL ASSETS | 3,110,000 | 3,110,000 | 3,461,000 | ||||||
Current liabilities | 3,909,000 | 3,909,000 | 975,000 | ||||||
Noncurrent liabilities | 2,868,000 | 2,868,000 | 5,680,000 | ||||||
Deficit | (3,667,000) | (3,667,000) | (3,194,000) | ||||||
TOTAL LIABILITIES AND EQUITY | 3,110,000 | 3,110,000 | 3,461,000 | ||||||
Related Party [Member] | CB Oncology Partners LLC [Member] | |||||||||
CB Oncology Partners [Abstract] | |||||||||
Due from related parties | 15,000 | 15,000 | 6,000 | ||||||
CB Oncology Partners LLC [Member] | |||||||||
CB Oncology Partners [Abstract] | |||||||||
Ownership percentage | 30.23% | 28.58% | 24% | ||||||
Capital called from members | $ 200,000 | $ 500,000 | |||||||
Advances converted into equity | 57,000 | 121,000 | |||||||
Contribution in cash | $ 76,000 | $ 212,000 | |||||||
Outstanding amount | 565,000 | 565,000 | $ 163,000 | ||||||
USNC's equity in (loss) income | (91,000) | (55,000) | (173,000) | (68,000) | |||||
Condensed Income Statement Information [Abstract] | |||||||||
USNC's equity in (loss) income | $ (91,000) | $ (55,000) | $ (173,000) | $ (68,000) |
Elite Health (Details)
Elite Health (Details) | Oct. 01, 2021 |
Elite Health Plan, Inc. [Member] | |
Elite Health [Abstract] | |
Equity consideration, percentage of outstanding shares | 15% |
Income Taxes (Details)
Income Taxes (Details) | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Income Taxes [Abstract] | ||
Federal and state income taxes, rate | 0% | 0% |